INNOVATE    •    INTERACT    •    INVEST


Cello Health BioConsultingCello Health

Cancer Progress Conference 2022 Panels

Patients Front and Center

How to Catch and Treat Cancer Early

Stage of the Art in Immuno-Oncology: Beyond PDx Inhibitors – or Not So Much

The Latest Potential “Paradigm-Shifters”

ADC “The Next Generation”

Biotechs to Go It Alone: Launch Strategy for Success

China Panel

How to Value Value: HEOR, HTA, ICER & Other Scary Acronyms for Oncology Developers!

What’s Hot/What’s Not for Startups in the Quasi-Post-Pandemic Oncology World?

Biotech versus Pharma Perspectives: Clinical Development Strategy

Cancer Vaccines Redux: mRNA, Oncolytic Viruses, Or Good Old-Fashioned Peptides: Is It the Target(s), Immunization Platform, Clin Dev Strategy, or All of the Above?

Does RNA Rule the World?

Degraders

Growing Pains: Navigating the Precipitous Path Towards Commercialization

Tortoises and Hares: De-risking Strategies Towards Multiplexed Candidates

Selling the Cell: Cost-benefit Considerations for Complex Therapeutics

Building on Success: Clinical and Commercial Dynamics in Heme Malignancies and Hematopoietic Transplantation

Tools of the Trade: Strategic Positioning of Emerging Cell Types, Target Discovery Engines, and Gene Engineering Tools

Leading Companies and Institutions that attended Cancer Progress 2021

  • AbbVie Ventures (tentative)
  • Abintus Bio
  • Adaptive Biotechnologies Corp.
  • Adicet Therapeutics
  • ADVI Health
  • Affimed
  • Aleta Biotherapeutics
  • Alloplex Biotherapeutics
  • Amphivena Therapeutics Inc
  • Arsenal Capital Partners
  • Ascentage Pharma
  • Astellas
  • Atossa Therapeutics
  • Bayer
  • BeiGene
  • BioInvent International
  • BresMed
  • Caribou Biosciences, Inc.
  • Carisma Therapeutics Inc.
  • Cartherics
  • Cello Health BioConsulting
  • Clinical Accelerator and Venture Fund, Cancer Research Institute
  • Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center
  • Compass Therapeutics
  • Crescendo Biologics Ltd
  • Cytovia Therapeutics
  • Dana-Farbe Cancer Institute
  • Fate Theraputics
  • Fred Hutchinson Cancer Center
  • F-star Biotech
  • Hillhouse Capital Management
  • I-Mab Biopharma
  • IGM Biosciences
  • Immatics
  • in8bio
  • IO Biotech
  • Ipsen
  • KAPital Consulting LLC
  • kuur
  • Leukemia & Lymphoma Society
  • Lilly Asia Ventures
  • Loxo Oncology at Lilly
  • Marker Therapeutic
  • MD Anderson Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • Merck & Co., Inc
  • Nanobiotix
  • Nanostring Technology
  • National Foundation for Cancer Research
  • NCI
  • Notch Therapeutics
  • Obsidian Therapeutics, Inc.
  • Pfizer Inc.
  • Shattuck Labs, Inc.
  • Silverback Therapeutics
  • Sofinnova Investments
  • Spotlight Therapeutics
  • Stanford Comprehensive Cancer Institute, Stanford University
  • Strand Therapeutics
  • The Institute of Cancer Research
  • The University of Texas MD Anderson Cancer Center
  • Tminuty Therapeutics Inc
  • Torreya
  • Triumvera
  • University of Chicago
  • University of Colorado School of Medicine
  • Venture Investments, The Mark Foundation
  • Vertex Ventures
  • Vor Bio Pharm
  • WindMIL

Thank you to our Cancer Progress 2021 Sponsors

Platinum Partnering Sponsor
Gold Sonsors
Silver Sponsors
Bronze Sponsors
  
Promotional Partners

Testimonials

Good array of opinions and technologies. Well curated

Andrew Allen, MD, PhD, President & CEO

Gritstone Oncology

As I like to say, Cancer Progress is THE BEST non-academic cancer conference out there. Again proving your staggering insight!

Michael G. King, Jr., Entrepreneur in Residence

Fortress Biotech Inc.

When we hear all the negatives from the experts on cell therapies and COVID—let’s think of Richard Feynman: “Science is the belief in the ignorance of the experts

Mark Simon, Managing Director

Torreya

“Thank you for the opportunity. I felt privileged to be part of a panel composed of stellar leaders within the Oncology space.”

Noemi Rosa

Novartis

“I really enjoyed the meeting as usual – great topics and speakers. I look forward to next year’s meeting!”

Richard Brian Gaynor, Sr. Vice President Global Development / Medical Affairs, Oncology Business Unit

Eli Lilly and Company